N/A
Completed N=80
Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
peripheral neuropathy · Stage 0 Breast Cancer · Stage I Breast Cancer · Stage IA Breast Cancer
Source: ClinicalTrials.gov NCT03139435 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcomePrimary: Tibial Nerve Cross-sectional Area — 13.0; 14.0 mm^2
Summary
This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tibial Nerve Cross-sectional Area |
13.0; 14.0 | — |
| SECONDARY Amplitude of Nerve Response - Ankle |
0.15 | — |
| SECONDARY Conduction Velocity of Nerve Response - Tibial |
0.15 | — |
| SECONDARY Distal Latency of Nerve Response - Ankle |
-0.23 | — |
| SECONDARY Nerve Fiber Density in the Skin |
-0.12 | — |
| SECONDARY Self-reported Neuropathy Score |
-0.18 | — |
| SECONDARY Sural Nerve Cross-sectional Area |
0.30 | — |
Eligibility Criteria
Inclusion Criteria
- Breast cancer (any stage)
- Previously or currently receiving taxane-based chemotherapy
- Clinical symptoms of peripheral neuropathy noted in medical record and suspected to be secondary to taxane-based therapy
- Ability and willingness to understand and sign an informed consent
Exclusion Criteria
- Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of taxane chemotherapy
- Unable to provide history
Data sourced from ClinicalTrials.gov (NCT03139435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.